| Date | Title | | | December 19, 2012 | Incyte to Present at the 31st Annual J. P. Morgan Healthcare Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 19, 2012--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
31st Annual J. P. Morgan Healthcare Conference on Monday,
January 7th at 8:30 a.m. (PST) / 11:30 a.m. (EST) in San
Francisco.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available for 90 days. Investo... |
|  | | December 10, 2012 | New Data for Jakafi® (ruxolitinib) Presented at the 2012 American Society of Hematology Annual Meeting|
In long-term results from two randomized Phase III clinical
trials (COMFORT-I and COMFORT-II), patients with myelofibrosis treated
with Jakafi had improved survival over placebo and best available
therapy, suggesting an overall survival benefit
Data from an ongoing Phase II trial suggest that long-term
treatment with Jakafi may be a durably efficacious therapy for
patients with polycythemia vera
... |
| | | December 07, 2012 | New Data for Jakafi® (ruxolitinib) to Be Presented at the 2012 American Society of Hematology Annual Meeting|
Incyte to host a webcast for investors featuring highlights from
multiple presentations on Monday, Dec. 10 at 8:45 p.m. EST
WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 7, 2012--
Incyte Corporation (Nasdaq: INCY) announced today that several analyses
from clinical studies of Jakafi® (ruxolitinib) will be presented at the
2012 American Society of Hematology (ASH) Annual Meeting from Dec. 8 to
11 at the Georgia World Congress Center in Atlanta. Jaka... |
| | | November 28, 2012 | Incyte to Present at the Oppenheimer 23rd Annual Healthcare Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 28, 2012--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
Oppenheimer 23rd Annual Healthcare Conference on Thursday,
December 13 at 1:35 p.m. (EST) in New York.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available for 90 days. Investors interested in
listen... |
| | | November 19, 2012 | Incyte to Present at the 24th Annual Piper Jaffray Healthcare Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 19, 2012--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
24th Annual Piper Jaffray Healthcare Conference on Tuesday,
November 27th at 1:30 p.m. (EST) in New York.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available for 60 days. Investors interested in
lis... |
| | | November 15, 2012 | Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid Arthritis| WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 15, 2012--
Incyte Corporation (NASDAQ: INCY) announced today that it has earned a
$50 million milestone payment from Eli Lilly and Company based on the
formal initiation of the rheumatoid arthritis (RA) Phase III program for
baricitinib, Incyte’s oral JAK1/JAK2 inhibitor, formerly known as
INCB28050. The Phase III program is being conducted by Lilly as part of
the exclusive worldwide License, Development and Co... |
| | | November 13, 2012 | Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis| - Baricitinib advancing into Phase III trials for rheumatoid arthritis -
Lilly and Incyte to host a webcast for investors featuring these results today, Nov. 13 at 7 p.m. ET
WASHINGTON, Nov. 13, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) today announced 24-week results from the continuation of an ongoing Phase IIb study of baricitinib, an orally available janus kinase (JAK) inhibitor, in patients with moderate-to-severe rheumatoid arthritis... |
| | | November 05, 2012 | Incyte to Present at the Jefferies 2012 Global Healthcare Conference (London)| WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 5, 2012--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
Jefferies 2012 Global Healthcare Conference on Thursday, November 15 at
3:00 p.m. (GMT) / 10:00 a.m. (EST) in London.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available for 90 days. Investors interested in... |
| | | November 01, 2012 | Incyte Reports 2012 Third-Quarter Financial Results; Updates Shareholders on Launch of Jakafi and Lead Clinical Programs|
$43.7 million of Jakafi® (ruxolitinib)
recognized as third-quarter U.S. net product revenue including $9.0
million of previously deferred revenue
Third quarter dispenses to patients increased 16 percent over
second quarter
Ruxolitinib approved for use in the European Union
Conference Call Scheduled Today at 8:30 a.m. ET
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 1, 2012--... |
| | | October 22, 2012 | Jim Daly to Join Incyte as Executive Vice President and Chief Commercial Officer| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 22, 2012--
Incyte Corporation (Nasdaq:INCY) today announced that Jim Daly has
joined Incyte as Executive Vice President and Chief Commercial Officer,
reporting to Paul Friedman, M.D., Incyte's President and Chief Executive
Officer. Formerly Senior Vice President, North America Commercial
Operations at Amgen, Mr. Daly is joining Incyte effective today and will
serve on the executive leadership team, assuming res... |
| | | October 09, 2012 | Incyte to Report Third Quarter 2012 Financial Results on November 1| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 9, 2012--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its third quarter 2012 financial results conference call for 8:30 a.m.
ET on Thursday, November 1, 2012. The schedules for the press release
and conference call are as follows:
... |
| | | September 19, 2012 | National Myelofibrosis Awareness Day to Launch on September 20|
Patient advocacy coalition leads inaugural recognition day to raise
awareness about myelofibrosis, a rare, potentially life-threatening
blood cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 19, 2012--
Incyte Corporation (Nasdaq: INCY) today announced its support of the
first national Myelofibrosis Awareness Day, which will be held on Sept.
20, 2012. The inaugural recognition day is being led by the MPN
Coalition, a group of patient advo... |
| | | August 28, 2012 | Jakavi® (ruxolitinib) First Medication to Receive European Commission Approval to Treat Patients with Myelofibrosis| WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 28, 2012--
Incyte Corporation (Nasdaq: INCY) today announced that its strategic
collaborator, Novartis, received approval from the European Commission
for Jakavi® (INC424, ruxolitinib), an oral JAK 1 and JAK 2
inhibitor discovered by Incyte, for the treatment of disease-related
splenomegaly or symptoms in adult patients with primary myelofibrosis
(also known as chronic idiopathic myelofibrosis), post-polycythem... |
| | | August 23, 2012 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 23, 2012--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
following investor conferences during the month of September:
Robert W. Baird & Co. 2012 Health Care Conference on Wednesday,
September 5, 2012 at 10:10 a.m. (ET) in New York City;
Morgan Stanley Global Healthcare Conference on Wednesday, September
12, 2012 at 10:55 a.m. (ET) in New Yor... |
| | | August 03, 2012 | Incyte to Present at the 32nd Annual Canaccord Genuity Growth Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 3, 2012--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
32nd Annual Canaccord Genuity Growth Conference on Wednesday,
August 15 at 10:30 a.m. (ET) in Boston.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available for 90 days. Investors interested in
listenin... |
| | | August 02, 2012 | Incyte Reports 2012 Second-Quarter Financial Results; Updates Shareholders on Launch of Jakafi and Lead Clinical Programs |
$35.1 million of Jakafi® (ruxolitinib) shipped to specialty pharmacies during the second quarter; $29.7 million in second-quarter net product revenue based on the sell-through revenue recognition method*
Use of Jakafi to treat patients with intermediate or high-risk myelofibrosis further supported by multiple clinical presentations
Positive Phase IIb results of oral JAK1 and JAK2 inhibitor, baricitinib, in patients with active rheumatoid arthritis presented at EULAR
Conference Call Schedul... |
| | | July 16, 2012 | Incyte to Report Second Quarter 2012 Financial Results on August 2| WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 16, 2012--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its second quarter 2012 financial results conference call for 8:30 a.m.
ET on Thursday, August 2, 2012. The schedules for the press release and
conference call are as follows:
-- Q2 2012... |
| | | June 26, 2012 | Incyte to Present at the JMP Securities 7th Annual Healthcare Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 26, 2012--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
JMP Securities 7th Annual Healthcare Conference on Thursday,
July 12, 2012 at 12:00 p.m. (ET) in New York.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available for 90 days. Investors interested in
li... |
| | | June 08, 2012 | Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis| Results presented as a late breaker at EULAR 2012
BERLIN, June 8, 2012 /PRNewswire via COMTEX/ --Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA). The results were presented as a late-breaking oral presentation at the European League Against Rheumatism's (... |
| | | June 04, 2012 | Incyte Presents Results from a Phase I Trial of INCB024360, a Novel Oral Inhibitor of Indoleamine Dioxygenase-1 (IDO1), at ASCO|
Data demonstrate that INCB024360 achieves greater than 90
percent IDO1 inhibition at generally well-tolerated doses and may
represent a new treatment for advanced malignancies
CHICAGO--(BUSINESS WIRE)--Jun. 4, 2012--
Incyte Corporation (Nasdaq: INCY) presented preliminary results today
from the ongoing Phase I clinical trial for its oral indoleamine
dioxygenase-1 (IDO1) inhibitor, INCB024360, at the American Society of
... |
| | | June 04, 2012 | New Data for Jakafi® (ruxolitinib) Presented at 2012 ASCO Annual Meeting|
Data from an ongoing trial suggest a dosing strategy with Jakafi
that may be efficacious and well-tolerated in myelofibrosis patients
with low platelet counts
Further analysis of adverse events from Phase III data in
COMFORT-I indicates there is no withdrawal syndrome after
discontinuation of therapy with Jakafi
Phase III data from COMFORT-II provide further evidence that
patients wit... |
| | | May 23, 2012 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--May. 23, 2012--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
following investor conferences during the month of June:
Goldman Sachs 33rd Annual Global Healthcare Conference on
Wednesday, June 6, 2012 at 3:20 pm (PT) / 6:20 pm (ET) in Rancho Palos
Verdes;
Jefferies 2012 Global Healthcare Conference on Thursday, June 7, 2012
at 11:00 am (ET) i... |
| | | May 01, 2012 | Incyte to Present at the Bank of America Merrill Lynch 2012 Health
Care Conference| WILMINGTON, Del., May 01, 2012 (BUSINESS WIRE) --Incyte Corporation (Nasdaq: INCY) announced today it will present at the
Bank of America Merrill Lynch 2012 Health Care Conference on Tuesday,
May 15, 2012 at 11:20 a.m. (PT) / 2:20 p.m. (ET) in Las Vegas.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available for 90 days. Investors interested in
... |
| | | April 26, 2012 | Incyte Reports 2012 First-Quarter Financial Results; Updates
Shareholders on Commercial Activity and Key Clinical Programs|
$19.3 million in first-quarter net product revenue from JakafiTM
(ruxolitinib); $25.1 million of Jakafi shipped to
specialty pharmacies during the quarter
Phase III studies of Jakafi published in The New England Journal
of Medicine demonstrate significant clinical benefit for patients with
myelofibrosis
Conference Call Scheduled Today at 8:30 a.m. ET
WILMINGTON, Del., Apr 26, ... |
| | | April 20, 2012 | Incyte Announces EU Regulatory Milestone for Ruxolitinib| WILMINGTON, Del., Apr 20, 2012 (BUSINESS WIRE) --Incyte Corporation (Nasdaq: INCY) announced today a European
Union (EU) regulatory milestone from Novartis. The milestone includes a
$40 million payment earned based on the recommendation by the Committee
for Medicinal Products for Human Use (CHMP) of the European
Medicines Agency (EMA) for approval of ruxolitinib for the treatment of
disease-related splenomegaly or symptoms in adult patients with primary
... |
| | | April 10, 2012 | Incyte to Report First Quarter 2012 Financial Results on April 26| WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 10, 2012--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its first quarter 2012 financial results conference call for 8:30 a.m.
ET on Thursday, April 26, 2012. The schedules for the press release and
conference call are as follows:
... |
| | | February 29, 2012 | Phase III studies of Jakafi™ (ruxolitinib) published in The New England Journal of Medicine Demonstrate Significant Clinical Benefit for Patients with Myelofibrosis|
Results from the COMFORT-I and COMFORT-II Phase III trials show
Jakafi significantly reduced spleen volume and debilitating symptoms
associated with myelofibrosis (MF), a life-threatening blood cancer
Updated analysis from COMFORT-I suggests Jakafi may provide an
overall survival benefit as compared to placebo
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 29, 2012--
The New England Journal of Medicine (NEJM... |
| | | February 22, 2012 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 22, 2012--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
following investor conferences during the month of March:
Cowen and Company’s 32nd Annual Health Care Conference on
Monday, March 5, 2012 at 2:10 p.m. (ET) in Boston; and
Barclays Capital 2012 Global Healthcare Conference on Tuesday, March
13, 2012 at 2:00 p.m. (ET) in Miami
... |
| | | February 15, 2012 | Incyte Reports 2011 Fourth-Quarter and Full-Year Financial Results; Provides 2012 Financial Guidance; Updates Shareholders on Key Clinical Programs|
Jakafi™ (ruxolitinib) approved by the FDA for treatment of patients
with intermediate or high-risk myelofibrosis on November 16, 2011
$2.0 million in net fourth-quarter revenue from Jakafi and $2.3
million in net deferred revenue; $4.9 million of Jakafi shipped to
specialty pharmacies
Clinical benefits of Jakafi discussed in multiple presentations at
2011 ASH Annual Meeting
... |
| | | February 03, 2012 | Incyte to Present at the Leerink Swann 2012 Global Healthcare Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 3, 2012--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
Leerink Swann 2012 Global Healthcare Conference on Thursday, February
16, 2012 at 2:30 p.m. (ET) in New York.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available for 90 days. Investors interested in
... |
| | | January 26, 2012 | Incyte to Report Fourth Quarter/Year-End 2011 Financial Results on February 15| WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 26, 2012--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its fourth quarter/year-end 2011 financial results conference call for
8:30 a.m. ET on Wednesday, February 15, 2012. The schedules for the
press release and conference call are as follows:
-- Q4 & YE 2011 Press Release:
... |
| |
|
